ESMO25: On getting ahead of cancer, with J&J's Henar Hevia &...

In conversation with Johnson & Johnson experts at ESMO 2025, discussing T-cell-redirecting bispecific antibodies and the future of immunotherapy.

ESMO 2025: ITM's Dr Andrew Cavey on next-gen RPTs

At ESMO, pharmaphorum spoke with radiopharmaceutical biotech Isotope Technologies Munich SE (ITM) CEO Dr Andrew Cavey.

News and advice from an investor-CEO, with Milenko Cicmil

pharmaphorum caught up with Milenko Cicmil to talk about Tasca Therapeutics’ news at LSX: their first patient dosed for lead asset CP-383.

From prostate cancer to breast cancer: In conversation with ...

Exploring the unconventional to provide hope: Dr Jason Willi...